


Ro 363

Cat. No.:	HY-123268
CAS No.:	74513-77-2
Molecular Formula:	C ₁₉ H ₂₅ NO ₆
Molecular Weight:	363.4
Target:	Adrenergic Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Ro 363 is a potent and highly selective β_1 -adrenoceptor agonist. RO 363 is an effective inotropic stimulant, and is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility ^{[1][2][3]} .
IC₅₀ & Target	Caution: Product has not been fully validated for medical applications. For research use only. β_1 -adrenoceptor ^[1] Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite O, Monmouth Junction, NJ 08852, USA
In Vitro	Isolated perfused heart preparations from guinea-pigs developed arrhythmic contractions following the administration of Ro 363 in doses producing 70-100% of its maximal chronotropic responses ^[1] . RO 363 is approximately half as potent as (-)-Isoprenaline in tissues where actions are due to β_1 -receptor activation (guinea-pig atrial and ileal preparations and ventricular strips from the rabbit, rat and guinea-pig ^[2] . In spontaneously contracted tracheal preparations from the guinea-pig, RO 363 is a full agonist and is approximately half as potent as (-)-Isoprenaline. These effects of RO 363 are due to the activation of a population of β_1 -receptors in the tissue since RO 363 and (-)-Isoprenaline have the same relative potencies in trachea, cardiac and ileal preparations ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	In chloralose-anaesthetized cats, Ro 363, when compared to epinephrine (adrenaline), is essentially devoid of arrhythmogenic activity in animals in which cardiac sensitization is induced by U-0882 or halothane ^[1] . Ro 363 elicits ventricular arrhythmias following the administration of subarrhythmic doses of ouabain and increases the number of subauricular escape beats which occurred during vagal nerve stimulation in non-ouabain treated animals ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Maccarrone C, et al. Comparison of the Arrhythmogenic Actions of (-)-Isoprenaline, Dobutamine and the selective beta 1-adrenoceptor agonist, (+/-)-(1-[3',4'-dihydroxyphenoxy]-2-hydroxy-3",4"-dimethoxy phenethylamino)-propane)-oxalate (Ro 363). *Arzneimittelforschung*. 1985;35(3):592-8.
- [2]. Iakovidis D, et al. In vitro activity of RO363, a beta1-adrenoceptor selective agonist. *Br J Pharmacol*. 1980 Apr;68(4):677-85.
- [3]. Einstein R, et al. Comparison of the cardiac effects of beta-adrenoceptor agonists in anaesthetised and conscious dogs. *J Auton Pharmacol*. 1986 Mar;6(1):9-14.